BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Körper S, Jahrsdörfer B, Corman VM, Pilch J, Wuchter P, Blasczyk R, Müller R, Tonn T, Bakchoul T, Schäfer R, Juhl D, Schwarz T, Gödecke N, Burkhardt T, Schmidt M, Appl T, Eichler H, Klüter H, Drosten C, Seifried E, Schrezenmeier H. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfus Med Hemother 2021;48:137-47. [PMID: 34177417 DOI: 10.1159/000515610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gachoud D, Pillonel T, Tsilimidos G, Battolla D, Dumas D, Opota O, Fontana S, Vollenweider P, Manuel O, Greub G, Bertelli C, Rufer N. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. Br J Haematol 2022. [PMID: 36101920 DOI: 10.1111/bjh.18450] [Reference Citation Analysis]
2 Chunchu SR, Ravula U, Gente VK, Bacchu S, Pandu Ranga Rao S, Mooli S. SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01512-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Grujić J, Bujandrić N, Budakov-Obradović Z, Dolinaj V, Bogdan D, Savić N, Cabezas-Cruz A, Mijatović D, Simin V, Anđelić N, Banović P. Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors. Int J Environ Res Public Health 2021;19:42. [PMID: 35010301 DOI: 10.3390/ijerph19010042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, Grüner B, Ernst L, Spieth P, Lepper PM, Bentz M, Zinn S, Paul G, Kalbhenn J, Dollinger MM, Rosenberger P, Kirschning T, Thiele T, Appl T, Mayer B, Schmidt M, Drosten C, Wulf H, Kruse JM, Jungwirth B, Seifried E, Schrezenmeier H; CAPSID Clinical Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest 2021;131:e152264. [PMID: 34464358 DOI: 10.1172/JCI152264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
5 Longueira Y, Polo ML, Turk G, Laufer N; InViV working group., Biobanco de Enfermedades Infecciosas Colección COVID19 working group. Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. Heliyon 2021;7:e08140. [PMID: 34642643 DOI: 10.1016/j.heliyon.2021.e08140] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Fabricius D, Ludwig C, Scholz J, Rode I, Tsamadou C, Jacobsen EM, Winkelmann M, Grempels A, Lotfi R, Janda A, Körper S, Adler G, Debatin KM, Schrezenmeier H, Jahrsdörfer B. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines (Basel) 2021;9:918. [PMID: 34452043 DOI: 10.3390/vaccines9080918] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]